PAI-1过表达促进食管鳞癌细胞的侵袭和迁移
收稿日期: 2019-12-31
修回日期: 2020-02-12
网络出版日期: 2020-02-27
基金资助
国家自然科学基金项目编号(81520108023);中国医学科学院医学与健康科技创新工程项目编号(2019-I2M-1-003);中国医学科学院医学与健康科技创新工程项目编号(2016-I2M-3-007);北京市科技新星项目资助编号(Z171100001117017)
PAI-1 overexpression promotes invasion and migration of esophageal squamous carcinoma cells
Received date: 2019-12-31
Revised date: 2020-02-12
Online published: 2020-02-27
Supported by
Supported by the National Natural Science Foundation of China No(81520108023);CAMS Innovation Fund for Medical Sciences Nos(2019-I2M-1-003);CAMS Innovation Fund for Medical Sciences Nos(2016-I2M-3-007);Beijing Nova Program No(Z171100001117017)
食管癌是常见的恶性肿瘤之一。由SERPINE1基因编码的纤溶酶原激活物抑制因子1 (plasminogen activator inhibitor-1, PAI-1)已被报道在多种类型癌症患者的肿瘤组织中存在高表达并参与癌症进展。为探讨PAI-1蛋白在食管鳞癌中的作用及其分子机制,本研究首先利用Western blot实验和酶联免疫吸附实验(enzyme linked immunosorbent assay, ELISA)检测各食管鳞癌细胞系中PAI-1的表达和分泌水平,结果显示,PAI-1高表达的食管鳞癌细胞系分泌至细胞外的PAI-1水平相对较高。进一步选取PAI-1表达及分泌水平均较高的KYSE150和KYSE450细胞系作为研究模型,通过siRNA(小干扰RNA)瞬时转染和Transwell实验证实敲降SERPINE1可显著抑制食管鳞癌KYSE150和KYSE450细胞的侵袭和迁移。同时,构建了慢病毒介导的SERPINE1稳定敲降细胞株KYSE150和KYSE450,将SERPINE1稳定敲降的细胞培养基中外源加入PAI-1蛋白进行 Transwell回复实验,结果表明PAI-1过表达可增强食管鳞癌细胞的侵袭和迁移能力。体内实验结果显示,降低PAI-1表达可显著抑制食管鳞癌细胞的成瘤和肺转移能力。分子水平检测表明PAI-1过表达可激活AKT和ERK信号通路,免疫共沉淀(co-immunoprecipitation, Co-IP)实验结果进一步显示PAI-1可能与膜受体LRP1 (LDL receptor related protein 1)存在相互作用。上述研究结果表明,PAI-1可能通过与LRP1相互作用进而促进食管鳞癌细胞的侵袭和迁移。
王迪, 杨荔艳, 刘奏, 余竟, 张敏杰, 张钰, 蔡岩, 徐昕, 郝佳洁, 王明荣 . PAI-1过表达促进食管鳞癌细胞的侵袭和迁移[J]. 遗传, 2020 , 42(3) : 287 -295 . DOI: 10.16288/j.yczz.19-334
Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers worldwide. Plasminogen activator inhibitor-1 (PAI-1), encoded by SERPINE1, is highly expressed in various types of tumor tissues, which contributes to cancer progression. The present study explored the role and underlying mechanisms of PAI-1 in ESCC. We found that the PAI-1 protein was extracellularly secreted more from ESCC cells with high PAI-1 expression using Western blotting and enzyme linked immunosorbent assay (ELISA). Knockdown of SERPINE1 expression significantly inhibited the invasion and migration of ESCC KYSE150 and KYSE450 cell lines, which could be restored when adding exogenous human recombinant PAI-1 into the culture medium of the cells stably expressing SERPINE1 shRNA. In vivo experiments showed that SERPINE1 knockdown significantly inhibited xenograft growth and lung metastasis of ESCC cells. Molecular analysis demonstrated that PAI-1 activated AKT and ERK signaling pathways. Co-immunoprecipitation (Co-IP) assays identified that PAI-1 may interact with the membrane receptor LDL receptor related protein 1 (LRP1). These results indicated that overexpression of PAI-1, through interacting with LRP1, might enhance invasion and migration of ESCC cells as well as promote ESCC progression.
| [1] | Chen WQ, Zheng RS, Baade PD, Zhang SW, Zeng HM, Bray F, Jemal A, Yu XQ, He J . Cancer statistics in China, 2015. CA Cancer J Clin, 2016,66(2):115-132. |
| [2] | Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin, 2015,65(2):87-108. |
| [3] | McMahon B, Kwaan HC . The plasminogen activator system and cancer. Pathophysiol Haemost Thromb, 2008,36(3-4):184-194. |
| [4] | Giacoia EG, Miyake M, Lawton A, Goodison S, Rosser CJ . PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation. Mol Cancer Res, 2014,12(3):322-334. |
| [5] | Xu J, Zhang WW, Tang L, Chen WW, Guan XX . Epithelial-mesenchymal transition induced PAI-1 is associated with prognosis of triple-negative breast cancer patients. Gene, 2018,670:7-14. |
| [6] | Zhang WW, Xu J, Fang HH, Tang L, Chen WW, Sun Q, Zhang Q, Yang F, Sun ZJ, Cao LL, Wang YC, Guan XX . Endothelial cells promote triple-negative breast cancer cell metastasis via PAI-1 and CCL5 signaling. FASEB J, 2018,32(1):276-288. |
| [7] | Lin X, Lin BW, Chen XL, Zhang BL, Xiao XJ, Shi JS, Lin JD, Chen X . PAI-1/PIAS3/Stat3/miR-34a forms a positive feedback loop to promote EMT-mediated metastasis through Stat3 signaling in Non-small cell lung cancer. Biochem Biophys Res Commun, 2017,493(4):1464-1470. |
| [8] | Nishioka N, Matsuoka T, Yashiro M, Hirakawa K, Olden K, Roberts JD . Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo. Cancer Sci, 2012,103(2):228-232. |
| [9] | Sakakibara T, Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A . Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma. Clin Cancer Res, 2004,10(4):1375-1378. |
| [10] | Placencio VR, DeClerck YA. Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. Cancer Res, 2015,75(15):2969-2974. |
| [11] | Kubala MH, Punj V, Placencio-Hickok VR, Fang H, Fernandez GE, Sposto R, DeClerck YA. Plasminogen activator inhibitor-1 promotes the recruitment and polarization of macrophages in cancer. Cell Rep, 2018, 25(8): 2177-2191.e7. |
| [12] | Wang CL, Hao JJ, Wu LF, Pan BQ, Xu X, Cai Y, Wang MR, Jia XM . IGHMBP2 overexpression promotes cell migration and invasion in esophageal squamous carcinoma. Hereditas (Beijing), 2015,37(4):360-366. |
| [12] | 王春丽, 郝佳洁, 吴李飞, 潘蓓青, 徐昕, 蔡岩, 王明荣, 贾雪梅 . IGHMBP2过表达促进食管鳞癌细胞的侵袭和迁移. 遗传, 2015,37(4):360-366. |
| [13] | Liu Z, Yu SB, Ye ST, Shen ZM, Gao L, Han ZY, Zhang PP, Luo F, Chen S, Kang MQ . Keratin 17 activates AKT signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma. J Proteomics, 2020,211:103557. |
| [14] | Ma S, Lu CC, Yang LY, Wang JJ, Wang BS, Cai HQ, Hao JJ, Xu X, Cai Y, Zhang Y, Wang MR . ANXA2 promotes esophageal cancer progression by activating MYC- HIF1A-VEGF axis. J Exp Clin Cancer Res, 2018,37(1):183. |
| [15] | Dellas C, Loskutoff DJ . Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost, 2005,93(4):631-640. |
| [16] | Peng Y, Kajiyama H, Yuan H, Nakamura K, Yoshihara M, Yokoi A, Fujikake K, Yasui H, Yoshikawa N, Suzuki S, Senga T, Shibata K, Kikkawa F . PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor- promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination. Cancer Lett, 2019,442:181-192. |
| [17] | Ferroni P, Roselli M, Portarena I, Formica V, Riondino S, LA Farina F, Costarelli L, Melino A, Massimiani G, Cavaliere F, Palmirotta R, Guadagni F . Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome. Anticancer Res, 2014,34(3):1153-1161. |
| [18] | Palmirotta R, Ferroni P, Savonarola A, Martini F, Ciatti F, Laudisi A, Sini V, Del Monte G, Guadagni F, Roselli M . Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res, 2009,124(4):403-408. |
| [19] | Che Y, Wang JN, Li Y, Lu ZL, Huang JB, Sun SG, Mao SS, Lei YY, Zang RC, Sun N, He J . Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance. Cell Death Dis, 2018,9(7):759. |
| [20] | Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N . Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts. J Cell Mol Med, 2019,23(4):2984-2994. |
| [21] | Fang HH, Jin J, Huang DD, Yang F, Guan XX . PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells. Cancer Sci, 2018,109(6):1949-1957. |
| [22] | Inoue M, Sawada T, Uchima Y, Kimura K, Nishihara T, Tanaka H, Yashiro M, Yamada N, Ohira M, Hirakawa K . Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis. Oncol Rep, 2005,14(6):1445-1451. |
| [23] | Geis T, D?ring C, Popp R, Grossmann N, Fleming I, Hansmann ML, Dehne N, Brüne B . HIF-2alpha-dependent PAI-1 induction contributes to angiogenesis in hepatocellular carcinoma. Exp Cell Res, 2015,331(1):46-57. |
| [24] | Mashiko S, Kitatani K, Toyoshima M, Ichimura A, Dan T, Usui T, Ishibashi M, Shigeta S, Nagase S, Miyata T, Yaegashi N . Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol Ther, 2015,16(2):253-260. |
| [25] | Pavón MA, Arroyo-Solera I, Téllez-Gabriel M, León X, Virós D, López M, Gallardo A, Céspedes MV, Casanova I, López-Pousa A, Mangues MA, Quer M, Barnadas A, Mangues R . Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients. Oncotarget, 2015,6(30):29016-29033. |
| [26] | Humphries BA, Buschhaus JM, Chen YC, Haley HR, Qyli T, Chiang B, Shen N, Rajendran S, Cutter A, Cheng YH, Chen YT, Cong J, Spinosa PC, Yoon E, Luker KE, Luker GD . Plasminogen Activator Inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple-negative breast cancer. Mol Cancer Res, 2019. 17(5):1142-1154. |
| [27] | Herz J, Strickland DK . LRP: a multifunctional scavenger and signaling receptor. J Clin Invest, 2001,108(6):779-784. |
| [28] | Cai Z, Qiao PF, Wan CQ, Cai M, Zhou NK, Li Q . Role of blood-brain barrier in Alzheimer's disease. J Alzheimers Dis, 2018,63(4):1223-1234. |
| [29] | Shinohara M, Tachibana M, Kanekiyo T, Bu G . Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies. J Lipid Res, 2017,58(7):1267-1281. |
| [30] | Holtzman DM, Herz J, Bu GJ . Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med, 2012,2(3):a006312. |
| [31] | Gheysarzadeh A, Ansari A, Emami MH, Razavi AE, Mofid MR . Over-expression of low-density lipoprotein receptor- related Protein-1 is associated with poor prognosis and invasion in pancreatic ductal adenocarcinoma. Pancreatology, 2019,19(3):429-435. |
| [32] | Feng CC, Ding GX, Ding Q, Wen H . Overexpression of low density lipoprotein receptor-related protein 1 (LRP1) is associated with worsened prognosis and decreased cancer immunity in clear-cell renal cell carcinoma. Biochem Biophys Res Commun, 2018,503(3):1537-1543. |
| [33] | Tian Y, Wang C, Chen S, Liu J, Fu Y, Luo Y . Extracellular Hsp90α and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1. J Cell Sci, 2019,132(15). |
| [34] | Salama Y, Lin SY, Dhahri D, Hattori K, Heissig B . The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis. FASEB J, 2019,33(3):3465-3480. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:
